Drugs / STL303
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07606365 | Jun 2026 → Jul 2028 expected | diffuse secondary choroid atrophy | Sitala Bio LTD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07606352 | Jun 2026 → Jul 2027 expected | IgA glomerulonephritis | Sitala Bio LTD | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STL303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07606365 ↗ |
| Route | Oral | “administered orally once daily” NCT07606352 ↗ |